The EBRD’s investment will support Famar’s ambitious growth plans, including the expansion of its production capacity and research and development (R&D) facilities in Greece.
Headquartered in Greece and with production sites in Greece, Italy and Spain, Famar is a leading pharmaceutical CDMO, focusing on the manufacturing and distribution of a wide range of pharmaceutical, consumer health and cosmetic products.
Under the new ownership, Famar plans to make substantial investments in Greece to expand both its R&D and sterile manufacturing capabilities, among others, as the company continues to shift its product mix towards higher-value-added products.
The EBRD started operating in Greece on a temporary basis in 2015 to support the country’s economic recovery. To date, the Bank has invested more than €7.9 billion in 115 projects in the corporate, financial, energy and infrastructure sectors of the Greek economy.
